In an interview to CNBC-TV18, Uday Baldota of Sun Pharma says the results of Taro, have been boosted by lack of competition and Forex gains. With 'very strong numbers' reported by Taro this quarter, Badola says its delisting process is still ongoing.
first published: Nov 14, 2011 02:29 pm
A collection of the most-viewed Moneycontrol videos.
TCS Q2 Earnings Live: Margin, Revenue Beat Street Estimates
Live: Nifty reclaims 25,100 ahead of TCS Q2 results; pharma, metals shine | Closing Bell
Canara Robeco AMC's Rs 1326 Cr IPO Kicks Off | Management Shares Growth Plans| IPO Watch Live
Live: Can Nifty hold above 25,000 as TCS begins Q2 results | Opening Bell
